Spondyloarthritis Clinical Trial
— SFASPAOfficial title:
Randomized Cross-over Pilot Study Evaluating the Effectiveness of Shiatsu on Fatigue in Patients With Axial Spondyloarthritis
Spondyloarthritis is a potentially serious disease with reduced life expectancy. Even if the clinical presentation is eminently variable from one patient to another, the most frequently encountered manifestations such as inflammatory spinal pain, peripheral arthritis or even extra-articular involvement of the disease all represent disabling symptoms, origin of pain, temporary or in some cases permanent functional incapacity, but also general repercussions on daily life (asthenia, reactive depressive syndrome, etc.) which require a multidisciplinary approach, involving several medical, paramedical and other stakeholders, The objective of treatment is to improve quality of life, to control symptoms and inflammation, to prevent structural damage, particularly in peripheral damage, to preserve or restore functional capacities, autonomy and social participation of patients with spondyloarthritis. In France, the main professional reference for shiatsu is the Syndicat des Professionnels de Shiatsu, which proposes the following definition to define shiatsu: Shiatsu (finger pressure in Japanese) is an energetic manual discipline addressing the individual as a whole. Shiatsu is part of personal assistance. He receives himself, dressed in soft clothes. Shiatsu is a discipline of well-being and prevention for better health. Its objective is to correct both the energy flow (ki, blood, lymph, etc.) and the body structure (muscles, tendons, etc.) by applying rhythmic pressure to the whole body, most often with the inches. It is for everyone and at all ages. Its principle of action is to restore the free flow of Ki (qi, Energy) in the body. Shiatsu is a set of pressures performed mainly with the thumbs and the palms of the hands on different areas of the body, often taking up the points of the acupuncture meridians. Shiatsu pressures can be (Ishizuka 1993; Kagotani 1984; Okamoto 2016): - mobile in a given place and lasting 3 to 5 seconds: a phase of increasing pressure followed by a short holding time then release, - static: same phases but with a hold time of up to approximately 1 minute or even longer. To date, there is no treatment specifically targeting fatigue in axSpA. Indeed, the underlying mechanisms of fatigue in SpA remain poorly understood, and could for example involve pro-inflammatory cytokines and the inflammatory process, and/or psychological distress. The effectiveness of non-pharmacological interventions and in particular the care provided by shiatsu practitioners have not been the subject of studies evaluating, according to the criteria of evidence-based medicine, the benefit of this practice, particularly in the context of treatment of spondyloarthritis.
| Status | Recruiting |
| Enrollment | 120 |
| Est. completion date | October 20, 2025 |
| Est. primary completion date | March 20, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility | Inclusion Criteria: - The patients with spondyloarthritis meeting the ASAS criteria and followed in the rheumatology department of the Orléans Regional Hospital Center. - Men and women aged 18 to 70 - Patients with digital or visual analog rating scale = 3 on the 1st question of the BASDAI Exclusion Criteria: - Patient with a pathology that contraindicates the practice of shiatsu (evolving infectious skin pathology that would make shiatsu treatment difficult) - Previous shiatsu treatment - Inability to attend appointments for the duration of the study - Pregnant or breastfeeding woman - Refusal to participate in the study or to sign the consent - Patients not affiliated or not beneficiaries of a social security scheme - Person under guardianship or curatorship - Patient with an uncontrolled epileptic or psychotic condition which, in the opinion of the investigator, would interfere with the smooth running of the study |
| Country | Name | City | State |
|---|---|---|---|
| France | CHR d'ORLEANS | Orleans |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Régional d'Orléans |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of patients responding to the FACIT Fatigue score | A response to fatigue will be defined as an improvement, i.e. an increase of = 4 points in the FACIT-F score corresponding to the minimum clinically important difference.
It is a short, easy to administer, 13-item tool that measures a person's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all tired to 0 = very tired) |
Day 0 | |
| Primary | Percentage of patients responding to the FACIT Fatigue score | A response to fatigue will be defined as an improvement, i.e. an increase of = 4 points in the FACIT-F score corresponding to the minimum clinically important difference.
It is a short, easy to administer, 13-item tool that measures a person's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all tired to 0 = very tired) |
Day 14 | |
| Primary | Percentage of patients responding to the FACIT Fatigue score | A response to fatigue will be defined as an improvement, i.e. an increase of = 4 points in the FACIT-F score corresponding to the minimum clinically important difference.
It is a short, easy to administer, 13-item tool that measures a person's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all tired to 0 = very tired) |
Day 28 | |
| Primary | Percentage of patients responding to the FACIT Fatigue score | A response to fatigue will be defined as an improvement, i.e. an increase of = 4 points in the FACIT-F score corresponding to the minimum clinically important difference.
It is a short, easy to administer, 13-item tool that measures a person's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all tired to 0 = very tired) |
Day 35 | |
| Secondary | Global Pain Evaluation (EVN) | The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms | Day 0 | |
| Secondary | Global Pain Evaluation (EVN) | The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms | Day 3 | |
| Secondary | Global Pain Evaluation (EVN) | The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms | Day 14 | |
| Secondary | Global Pain Evaluation (EVN) | The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms | Day 18 | |
| Secondary | Global Pain Evaluation (EVN) | The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms | Day 28 | |
| Secondary | Global Pain Evaluation (EVN) | The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms | Day 35 | |
| Secondary | Global Pain Evaluation (EVN) | The EVA pain scale is a graduated ruler ranging from 0 to 10. 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms | Day 56 | |
| Secondary | BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) | This is a questionnaire to calculate the activity index of ankylosing spondylitis.
The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 0 | |
| Secondary | BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) | This is a questionnaire to calculate the activity index of ankylosing spondylitis.
The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 3 | |
| Secondary | BASDAI Bath Ankylosing Spondylitis Disease Activity Index | This is a questionnaire to calculate the activity index of ankylosing spondylitis.
The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 14 | |
| Secondary | BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) | This is a questionnaire to calculate the activity index of ankylosing spondylitis.
The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 18 | |
| Secondary | BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) | This is a questionnaire to calculate the activity index of ankylosing spondylitis.
The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 28 | |
| Secondary | BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) | This is a questionnaire to calculate the activity index of ankylosing spondylitis.
The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. |
Day 35 | |
| Secondary | BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) | This is a questionnaire to calculate the activity index of ankylosing spondylitis.
The intensity of 5 symptoms during the past week will be estimated, giving a score from 0 to 10, knowing that 0 means the absence of the symptom and 10 its presence in the highest degree 0 = no pain 10 = maximum imaginable pain Pain will be assessed by the patient at each visit. Show the differences in disease progression between the 2 treatment arms |
Day 56 | |
| Secondary | BASFI questionnaire (Bath ankylosing spondylitis functional index) | It was developed specifically to assess joint mobility in SpA. The BASFI reflects the functional impact, that is to say the inability to perform actions of daily life. For each of the ten activities, you must rate from 0 to 10 the ease or difficulty of performing them during the past month. 0 means completely easy, 10 means impossible. This score is an aid in monitoring ankylosing spondylitis.
Show the differences in disease progression between the 2 treatment arms |
Day 0 | |
| Secondary | BASFI questionnaire (Bath ankylosing spondylitis functional index) | It was developed specifically to assess joint mobility in SpA. The BASFI reflects the functional impact, that is to say the inability to perform actions of daily life. For each of the ten activities, you must rate from 0 to 10 the ease or difficulty of performing them during the past month. 0 means completely easy, 10 means impossible. This score is an aid in monitoring ankylosing spondylitis.
Show the differences in disease progression between the 2 treatment arms |
Day 14 | |
| Secondary | BASFI questionnaire (Bath ankylosing spondylitis functional index) | It was developed specifically to assess joint mobility in SpA. The BASFI reflects the functional impact, that is to say the inability to perform actions of daily life. For each of the ten activities, you must rate from 0 to 10 the ease or difficulty of performing them during the past month. 0 means completely easy, 10 means impossible. This score is an aid in monitoring ankylosing spondylitis.
Show the differences in disease progression between the 2 treatment arms |
Day 28 | |
| Secondary | BASFI questionnaire (Bath ankylosing spondylitis functional index) | It was developed specifically to assess joint mobility in SpA. The BASFI reflects the functional impact, that is to say the inability to perform actions of daily life. For each of the ten activities, you must rate from 0 to 10 the ease or difficulty of performing them during the past month. 0 means completely easy, 10 means impossible. This score is an aid in monitoring ankylosing spondylitis.
Show the differences in disease progression between the 2 treatment arms |
Day 35 | |
| Secondary | Short Form-36 (SF-36) | It is a self-assessment quality of life scale comprising 11 questions
Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: |
Day 0 | |
| Secondary | Short Form-36 | It is a self-assessment quality of life scale comprising 11 questions
Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: |
Day 14 | |
| Secondary | Short Form-36 | It is a self-assessment quality of life scale comprising 11 questions.
Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: |
Day 28 | |
| Secondary | Short Form-36 | It is a self-assessment quality of life scale comprising 11 questions.
Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: |
Day 35 | |
| Secondary | AsQoL Questionnaire (Ankylosing Spondylitis Quality of Life Questionnaire) | Score validated in French in 2010(Pham et al. 2010), it is composed of 18 double-choice (yes/no) items. All the points obtained are added together and divided by the maximum possible total Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: AS Quality of Life (ASQOL) | Day 0 | |
| Secondary | AsQoL Questionnaire (Ankylosing Spondylitis Quality of Life Questionnaire) | Score validated in French in 2010(Pham et al. 2010), it is composed of 18 double-choice (yes/no) items. All the points obtained are added together and divided by the maximum possible total Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: AS Quality of Life (ASQOL) | Day 14 | |
| Secondary | AsQoL Questionnaire (Ankylosing Spondylitis Quality of Life Questionnaire) | Score validated in French in 2010(Pham et al. 2010), it is composed of 18 double-choice (yes/no) items. All the points obtained are added together and divided by the maximum possible total Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: AS Quality of Life (ASQOL) | Day 28 | |
| Secondary | AsQoL Questionnaire (Ankylosing Spondylitis Quality of Life Questionnaire) | Score validated in French in 2010(Pham et al. 2010), it is composed of 18 double-choice (yes/no) items. All the points obtained are added together and divided by the maximum possible total Show the differences in disease progression between the 2 treatment arms for Change in quality of life assessed according to the following indexes: AS Quality of Life (ASQOL) | Day 35 | |
| Secondary | BASMI measurement index | It allows to evaluate the mobility of the spine. It is composed of 5 items including: cervical rotation, tragus wall distance, lateral flexion of the spine, lumbar flexion and inter malleolar distance. The score for each item is added together to result in a rating out of 10. | Day 0 | |
| Secondary | BASMI measurement index | It allows to evaluate the mobility of the spine. It is composed of 5 items including: cervical rotation, tragus wall distance, lateral flexion of the spine, lumbar flexion and inter malleolar distance. The score for each item is added together to result in a rating out of 10. | Day 35 | |
| Secondary | SpA Patient Health Index (ASAS Health Index) | This self-assessment questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EFs) in patients with SpA. The ASAS HI contains items covering the following categories: pain, emotional functions, sleep, sexual functions, mobility, autonomy and community life | Day 0 | |
| Secondary | SpA Patient Health Index (ASAS Health Index) | This self-assessment questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EFs) in patients with SpA. The ASAS HI contains items covering the following categories: pain, emotional functions, sleep, sexual functions, mobility, autonomy and community life | Day 14 | |
| Secondary | SpA Patient Health Index (ASAS Health Index) | This self-assessment questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EFs) in patients with SpA. The ASAS HI contains items covering the following categories: pain, emotional functions, sleep, sexual functions, mobility, autonomy and community life | Day 28 | |
| Secondary | SpA Patient Health Index (ASAS Health Index) | This self-assessment questionnaire measures functioning and health across 17 aspects of health and 9 environmental factors (EFs) in patients with SpA. The ASAS HI contains items covering the following categories: pain, emotional functions, sleep, sexual functions, mobility, autonomy and community life | Day 35 | |
| Secondary | Work Productivity Index (WPAI) (Work Productivity and activity Impairment questionnaire) | This is a self-administered questionnaire where the assessment is based on the patient's absenteeism, his presence and his difficulties in carrying out his work or his outside activities. The higher the score, the more the patient has difficulty | Day 0 | |
| Secondary | Work Productivity Index (WPAI) (Work Productivity and activity Impairment questionnaire) | This is a self-administered questionnaire where the assessment is based on the patient's absenteeism, his presence and his difficulties in carrying out his work or his outside activities. The higher the score, the more the patient has difficulty | Day 14 | |
| Secondary | Work Productivity Index (WPAI) (Work Productivity and activity Impairment questionnaire) | This is a self-administered questionnaire where the assessment is based on the patient's absenteeism, his presence and his difficulties in carrying out his work or his outside activities. The higher the score, the more the patient has difficulty | Day 28 | |
| Secondary | Work Productivity Index (WPAI) (Work Productivity and activity Impairment questionnaire) | This is a self-administered questionnaire where the assessment is based on the patient's absenteeism, his presence and his difficulties in carrying out his work or his outside activities. The higher the score, the more the patient has difficulty | Day 35 | |
| Secondary | Anxiety and Depression (HAD) scale | The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores to be obtained (maximum score for each score = 21) | Day 0 | |
| Secondary | Anxiety and Depression (HAD) scale | The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores to be obtained (maximum score for each score = 21) | Day 14 | |
| Secondary | Anxiety and Depression (HAD) scale | The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores to be obtained (maximum score for each score = 21) | Day 28 | |
| Secondary | Anxiety and Depression (HAD) scale | The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores to be obtained (maximum score for each score = 21) | Day 35 | |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | This index is used to assess the sleep quality of subjects over the past month. The 17 scoring items in this study were combined into six components: sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorder, and daytime dysfunction.
Each component used a Likert4 score (scored from 0 to 3), and the scores were added to obtain a total of 0-21 points. The higher the PSQI index, the worse the quality of sleep. A PSQI >7 is considered indicative of a sleep disorder. |
Day 0 | |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | This index is used to assess the sleep quality of subjects over the past month. The 17 scoring items in this study were combined into six components: sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorder, and daytime dysfunction.
Each component used a Likert4 score (scored from 0 to 3), and the scores were added to obtain a total of 0-21 points. The higher the PSQI index, the worse the quality of sleep. A PSQI >7 is considered indicative of a sleep disorder. |
Day 14 | |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | This index is used to assess the sleep quality of subjects over the past month. The 17 scoring items in this study were combined into six components: sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorder, and daytime dysfunction.
Each component used a Likert4 score (scored from 0 to 3), and the scores were added to obtain a total of 0-21 points. The higher the PSQI index, the worse the quality of sleep. A PSQI >7 is considered indicative of a sleep disorder. |
Day 28 | |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | This index is used to assess the sleep quality of subjects over the past month. The 17 scoring items in this study were combined into six components: sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorder, and daytime dysfunction.
Each component used a Likert4 score (scored from 0 to 3), and the scores were added to obtain a total of 0-21 points. The higher the PSQI index, the worse the quality of sleep. A PSQI >7 is considered indicative of a sleep disorder. |
Day 35 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03564743 -
Description of Spondylarthritis and Validation of ASAS Criteria in West Indian Patients Seen in Consultation of Rheumatology.
|
||
| Completed |
NCT01219257 -
Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy
|
||
| Terminated |
NCT03232580 -
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
|
Phase 2 | |
| Recruiting |
NCT05039216 -
Biobank for Inflammatory Chronic Diseases and Osteoporosis
|
||
| Completed |
NCT04483648 -
Cervical Stabilization Exercises in Patients With Spondyloarthritis
|
N/A | |
| Recruiting |
NCT04602091 -
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
|
||
| Not yet recruiting |
NCT04077957 -
Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs
|
Phase 4 | |
| Recruiting |
NCT05290363 -
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
|
N/A | |
| Not yet recruiting |
NCT05006690 -
Telerehabilitation, Face-to-Face and Home-Based Spinal Stabilization Exercise Training in Patients With Spondyloarthritis
|
N/A | |
| Completed |
NCT02998398 -
Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
|
||
| Completed |
NCT02148640 -
The NOR-SWITCH Study
|
Phase 4 | |
| Completed |
NCT01174186 -
Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
|
Phase 4 | |
| Recruiting |
NCT04499001 -
Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Patients With Inflammatory Arthritis With Subcutaneous Biologic DMARDs
|
||
| Completed |
NCT03253796 -
Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
|
Phase 4 | |
| Active, not recruiting |
NCT04169373 -
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
|
Phase 3 | |
| Recruiting |
NCT04292067 -
Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis
|
||
| Completed |
NCT04946539 -
Value of Ultrasonographic Enthesitis Assessment in Spondyloarthritis
|
||
| Recruiting |
NCT03983473 -
Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.
|
N/A | |
| Terminated |
NCT03345355 -
MRI of Sacroiliac Joints: Evaluation of Accuracy of Dixon Sequences in the Diagnosis of Axial Spondyloarthritis
|
||
| Completed |
NCT04360785 -
Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis
|
N/A |